Mobile

A randomized, double-masked, active-controlled, multicenter study comparing the efficacy and safety ofranibizumab 0.3 mg and 0.5 mg administered as twodosing regimens in patients with subfoveal chor...

Update Il y a 5 ans
Reference: EUCTR2005-003517-33

A randomized, double-masked, active-controlled, multicenter study comparing the efficacy and safety ofranibizumab 0.3 mg and 0.5 mg administered as twodosing regimens in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

Inclusion criteria

  • Wet age-related macular degeneration of retina

Links